For Nexavar In Lung Cancer, Focus Moves From First To Second Line
This article was originally published in The Pink Sheet Daily
Executive Summary
Nexavar failed to meet the primary endpoint of a second Phase III trial in first-line lung cancer, but Bayer/Onyx remain optimistic about prospects for the drug in the disease based on biomarkers.
You may also be interested in...
Nexavar Expansion Plans Suffer Another Blow With Failed Lung Cancer Trial
Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer.
Nexavar Expansion Plans Suffer Another Blow With Failed Phase III Lung Cancer Trial
Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer, with ASCO presentations ahead.
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.